This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Novartis Reshapes Portfolio via GSK, Eli Lilly Deals

NEW YORK (The Deal) -- The battle against cancer has taken on a financial dimension, with Novartis (NVS - Get Report) agreeing to take a host of oncology drugs from GlaxoSmithKline  (GSK - Get Report) in the largest of four multi-billion transactions by the Swiss company, and Pfizer (PFE - Get Report) reportedly missing out in a run for AstraZeneca (AZN - Get Report) cancer treatments.

Novartis, of Basel, on Tuesday agreed to pay up to $16 billion for Uxbridge, England-based GlaxoSmithKline's oncology portfolio. The figure includes as much as $1.5 billion depending on the development of some medicines and also gives Novartis first rights to the U.K. company's oncology pipeline.

WATCH: More market update videos on TheStreet TV

The Swiss company will also sell its vaccine unit, minus flu vaccinations, to GlaxoSmithKline for as much as $7.1 billion, including $5.25 billion immediately and up to $1.8 billion in development milestones.

Novartis said it will launch a separate auction for the flu activities.

"The transactions mark a transformational moment for Novartis. They focus the company on leading businesses with innovation power and global scale," said Novartis CEO Joseph Jimenez in a statement.

Novartis and GlaxoSmithKline will also pool their over-the-counter medicine activities in to a joint venture that will be 36.5% owned by Novartis and make GlaxoSmithKline a consumer healthcare bulwark.

Finally, Novartis will sell its animal health business to Indianapolis-based Eli Lilly (LLY - Get Report) for $5.4 billion.

The transactions follow Jimenez' promise last year to take a hard look at the company's smaller businesses.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
AZN $69.86 0.00%
GSK $45.56 0.00%
LLY $74.27 0.00%
NVS $104.79 0.00%
PFE $34.36 0.00%


DOW 18,285.74 +0.34 0.00%
S&P 500 2,130.82 +4.97 0.23%
NASDAQ 5,090.7940 +19.0510 0.38%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs